Low dose CT screening cuts down lung cancer death rates

Low dose CT screening cuts down lung cancer death rates

William C. Black et al reported continued benefit related to lung cancer mortality with low-dose computed tomography (LDCT) screening on extended follow-up of participants in the National Lung Screening Trial (NLST). The 2011 NLST had reported a 20% reduction in lung cancer mortality in high-risk current and former smokers screened annually for 3 years with LDCT as compared to chest X-rays. The study involved 26,722 patients in the LDCT arm and 26,730 in the X-ray arm. The current follow-up estimated that a total of 303 persons need to be screened to prevent 1 death from lung cancer; compared to 320 persons to prevent 1 death from lung cancer reported in the 2011 study. The latest study extended the follow up to 6 years evaluating a total of 12.3 years for mortality. The researchers report that the extended follow-up allowed them to determine that LDCT did, in fact, prevent lung cancer death or at least delayed them for more than a decade. Overall mortality reported nearly 5,253 deaths in the LDCT group and 5,366 deaths in the chest X-ray arm. The study also reaffirms the findings from the NELSON trial, which found a 26% reduction in lung cancer mortality in men and a 39% reduction in women with the use of LDCT.

Source:  Journal of Thoracic Oncology 28 June 2019  DOI: 10.1016/j.jtho.2019.05.044 https://www.jto.org/article/S1556-0864(19)30473-3/fulltext

Straight Talk

View More